InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

Benzinga01-05

InflaRx N.V. (NASDAQ:IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601129886?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/05/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-01-05 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601129886","market":"hk","top_or_hot":-1,"title":"InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder","media":"Benzinga","content":"<div>\n<p>InflaRx N.V. (NASDAQ:IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49687006/inflarx-reopens-case-for-axed-phase-3-drug-for-rare-skin-disorder\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-05 20:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/01/49687006/inflarx-reopens-case-for-axed-phase-3-drug-for-rare-skin-disorder><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>InflaRx N.V. (NASDAQ:IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49687006/inflarx-reopens-case-for-axed-phase-3-drug-for-rare-skin-disorder\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014575.USD","symbol_name":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/01/49687006/inflarx-reopens-case-for-axed-phase-3-drug-for-rare-skin-disorder","article_id":"2601129886","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/05/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/01/49687006/inflarx-reopens-case-for-axed-phase-3-drug-for-rare-skin-disorder","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601129886","pubTimestamp":1767614880,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"InflaRx N.V.  is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led path forward.Last Tuesday, the company outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum , which was terminated earlier in 2025 after an Independent Data Monitoring Committee  recommended the trial be stopped early due to futility.Subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect, the company said.Pyoderma gangrenosum  is a rare, painful skin condition characterized by red bumps that quickly develop into large, deep, open ulcers, often with a purple, undermined border, although it’s not caused by infection or gangrene.In addition, patients reported feeling better as measured by the Dermatology Life Quality Index  mean percentage change at the end of the treatment visi","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IFRX":"InflaRx N.V.","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","PG":"宝洁","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","BK4018":"居家用品","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4534":"瑞士信贷持仓","BK4504":"桥水持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4558":"双十一","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU2097829019.USD":"AZ EQUITY - BORLETTI GLOBAL LIFESTYLE \"AI\" (USD) ACC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B"},"translate_title":"InflaRx重新启动被砍掉的治疗罕见皮肤病的3期药物案例","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IFRX":1,"PG":1},"content_text":"InflaRx N.V. (NASDAQ:IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led path forward.\nLast Tuesday, the company outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum (PG), which was terminated earlier in 2025 after an Independent Data Monitoring Committee (IDMC) recommended the trial be stopped early due to futility.\nSubsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect, the company said.\nAlso Read: Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability\nPyoderma gangrenosum (PG) is a rare, painful skin condition characterized by red bumps that quickly develop into large, deep, open ulcers, often with a purple, undermined border, although it’s not caused by infection or gangrene.\nAs next steps, InflaRx anticipates meeting with the FDA to discuss a potential path forward for vilobelimab in PG, including the use of alternative endpoints that could be utilized for potential future clinical studies.\nIn an effort to prioritize izicopan (INF904) development, InflaRx does not expect to deploy significant resources towards future vilobelimab development in PG on its own and will instead consider doing so in collaboration with a partner.\nIn November 2025, InflaRx revealed topline data from a Phase 2a basket study exploring INF904 in hidradenitis suppurative and chronic spontaneous urticaria.\nThe analyses disclosed on Tuesday include the primary intent-to-treat analysis and several post-hoc analyses on the 54 patients enrolled in the trial at the time of study termination.\nThe primary clinical endpoint of complete target ulcer closure on two consecutive visits showed a difference in favor of vilobelimab over placebo of 20.8% versus 16.7% (p=NS (not significant)).\nKey secondary endpoints, such as complete disease remission (complete closure of all ulcers), showed improvement in favor of vilobelimab over placebo (20.8% versus 5.6%, p=NS) and those with >50% reduction of target ulcer volume at week 26 (36.4% versus 16.7%, p=NS).\nIn addition, patients reported feeling better as measured by the Dermatology Life Quality Index (DLQI) mean percentage change at the end of the treatment visit (-31.1% versus 3.4%).\nOverall, vilobelimab was well tolerated.\nIn addition, further post-hoc analyses showed that there is an overall treatment effect with vilobelimab when compared to placebo.\nThese include an MMRM (mixed model repeated measures) for percent change in target ulcer volume, which showed an average effect over all visits in favor of vilobelimab over placebo (-45.4%, p=0.0428, Weeks 2 – 26 overall) when imputing patients with treatment-related discontinuation reasons.\nThe analysis yielded a significant treatment difference for every week from Week 14 (-57.6%, p=0.0357) to Week 26 (-63.2%, p=0.0122) for vilobelimab over placebo.\nThe analyses also suggest that treatment longer than 26 weeks with vilobelimab may provide improved treatment outcomes.\nIFRX Price Action: IFRX stock closed at $1.09, up 7.92% on Friday, according to Benzinga Pro data.\nRead Next:\nPhoto by Gorodenkoff via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601129886","isCrawlerRequest":true}